Neurosteroid agonist at GABAA receptor induces persistent neuroplasticity in VTA dopamine neurons

Neuropsychopharmacology

Volumn 39, Issue 3, 2014, Pages 727-737

  Vashchinkina, Elena ^a   Manner, Aino K ^a   Vekovischeva, Olga ^a   Hollander, Bjørnar Den ^a   Uusi Oukari, Mikko ^b   Aitta Aho, Teemu ^a   Korpi, Esa R ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

AMPA receptors; aversive conditioning; d subunit knockout mice; dopamine neurons; ganaxolone; tonic inhibition

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; GANAXOLONE; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID; NEUROSTEROID; 4 AMINOBUTYRIC ACID; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; AMINO ACID RECEPTOR AFFECTING AGENT; DOPAMINE; DRUG DERIVATIVE; ELTANOLONE; GABAERGIC RECEPTOR AFFECTING AGENT; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 1; GREEN FLUORESCENT PROTEIN; PICROTOXIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; COGNITION; CONDITIONING; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG DEPENDENCE; EMOTION; FEMALE; INTERNEURON; KNOCKOUT MOUSE; MALE; MOOD; MOTIVATION; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SINGLE DRUG DOSE; VENTRAL TEGMENTUM; ACTION POTENTIAL; ANIMAL; C57BL MOUSE; CYTOLOGY; DRUG EFFECT; GENETICS; IN VITRO STUDY; METABOLISM; TRANSGENIC MOUSE;

ACTION POTENTIALS; ANIMALS; DOPAMINE; DOPAMINERGIC NEURONS; EXCITATORY AMINO ACID AGENTS; FEMALE; GABA AGENTS; GAMMA-AMINOBUTYRIC ACID; GLUTAMATE DECARBOXYLASE; GREEN FLUORESCENT PROTEINS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEURONAL PLASTICITY; NEUROTRANSMITTER AGENTS; PICROTOXIN; PREGNANOLONE; RECEPTORS, GABA-A; VENTRAL TEGMENTAL AREA;

EID: 84892670088     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.258     Document Type: Article

References (50)

1. Aitta-aho T, Moykkynen TP, Panhelainen AE, Vekovischeva OY, Backstrom P, Korpi ER (2012). Importance of GluA1 subunitcontaining AMPA glutamate receptors for morphine statedependency. PLoS One 7: e38325.
2. Anker JJ, Zlebnik NE, Carroll ME (2010). Differential effects of allopregnanolone on the escalation of cocaine self-administration and sucrose intake in female rats. Psychopharmacology (Berl) 212: 419-429.
3. Backstrom T, Haage D, Lofgren M, Johansson IM, Stromberg J, Nyberg S et al (2011). Paradoxical effects of GABA-A modulators may explain sex steroid induced negative mood symptoms in some persons. Neuroscience 191: 46-54.
4. Bagetta V, Sgobio C, Pendolino V, Del Papa G, Tozzi A, Ghiglieri V et al (2012). Rebalance of striatal NMDA/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease. J Neurosci 32: 17921-17931.
5. Beauchamp MH, Ormerod BK, Jhamandas K, Boegman RJ, Beninger RJ (2000). Neurosteroids and reward: allopregnanolone produces a conditioned place aversion in rats. Pharmacol Biochem Behav 67: 29-35.
6. Carter RB, Wood PL, Wieland S, Hawkinson JE, Belelli D, Lambert JJ et al (1997). Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3a-hydroxy-3b-methyl-5a-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acidA receptor. J Pharmacol Exp Ther 280: 1284-1295.
7. Cunningham CL, Niehus JS (1993). Drug-induced hypothermia and conditioned place aversion. Behav Neurosci 107: 468-479.
8. Cunningham CL, Gremel CM, Groblewski PA (2006). Druginduced conditioned place preference and aversion in mice. Nat Protoc 1: 1662-1670.
9. den Hollander B, Rozov S, Linden AM, Uusi-Oukari M, Ojanpera I, Korpi ER (2013). Long-term cognitive and neurochemical effects of 'bath salt' designer drugs methylone and mephedrone. Pharmacol Biochem Behav 103: 501-509.
10. Dingledine R, Borges K, Bowie D, Traynelis SF (1999). The glutamate receptor ion channels. Pharmacol Rev 51: 7-61.
11. Fancsik A, Linn DM, Tasker JG (2000). Neurosteroid modulation of GABA IPSCs is phosphorylation dependent. J Neurosci 20: 3067-3075.
12. File SE (1986). Aversive and appetitive properties of anxiogenic and anxiolytic agents. Behav Brain Res 21: 189-194.
13. Finn DA, Phillips TJ, Okorn DM, Chester JA, Cunningham CL (1997). Rewarding effect of the neuroactive steroid 3a-hydroxy-5a-pregnan-20-one in mice. Pharmacol Biochem Behav 56: 261-264.
14. Gee KW, McCauley LD, Lan NC (1995). A putative receptor for neurosteroids on the GABAA receptor complex: the pharmacological properties and therapeutic potential of epalons. Crit Rev Neurobiol 9: 207-227.
15. Glykys J, Mody I (2007). The main source of ambient GABA responsible for tonic inhibition in the mouse hippocampus. J Physiol 582: 1163-1178.
16. Glykys J, Mann EO, Mody I (2008). Which GABAA receptor subunits are necessary for tonic inhibition in the hippocampus? J Neurosci 28: 1421-1426.
17. Gong S, Zheng C, Doughty ML, Losos K, Didkovsky N, Schambra UB et al (2003). A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature 425: 917-925.
18. Heikkinen AE, Moykkynen TP, Korpi ER (2009). Long-lasting modulation of glutamatergic transmission in VTA dopamine neurons after a single dose of benzodiazepine agonists. Neuropsychopharmacology 34: 290-298.
19. Hosie AM, Wilkins ME, da Silva HM, Smart TG (2006). Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites. Nature 444: 486-489.
20. Introini-Collison IB, Castellano C, McGaugh JL (1994). Interaction of GABAergic and b-noradrenergic drugs in the regulation of memory storage. Behav Neural Biol 1: 150-155.
21. Kalivas PW, Duffy P, Eberhardt H (1990). Modulation of A10 dopamine neurons by g-aminobutyric acid agonists. J Pharmacol Exp Ther 253: 858-866.
22. Korpi ER, Mihalek RM, Sinkkonen ST, Hauer B, Hevers W, Homanics GE et al (2002). Altered receptor subtypes in the forebrain of GABAA receptor d subunit-deficient mice: recruitment of g2 subunits. Neuroscience 109: 7337-7343.
23. Kramer PF, Christensen CH, Hazelwood LA, Dobi A, Bock R, Sibley DR et al (2011). Dopamine D2 receptor overexpression alters behavior and physiology in Drd2-EGFP mice. J Neurosci 31: 126-132.
24. Lambert JJ, Belelli D, Peden DR, Vardy AW, Peters JA (2003). Neurosteroid modulation of GABAA receptors. Prog Neurobiol 71: 67-80.
25. Lambert JJ, Cooper MA, Simmons RD, Weir CJ, Belelli D (2009). Neurosteroids: endogenous allosteric modulators of GABAA receptors. Psychoneuroendocrinology 34(Suppl 1): S48-S58.
26. Lammel S, Ion DI, Roeper J, Malenka RC (2011). Projectionspecific modulation of dopamine neuron synapses by aversive and rewarding stimuli. Neuron 70: 855-862.
27. Luscher C, Malenka RC (2011). Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling. Neuron 69: 650-663.
28. Margolis EB, Toy B, Himmels P, Morales M, Fields HL (2012). Identification of rat ventral tegmental area GABAergic neurons. PLoS ONE 7: e42365.
29. Marowsky A, Rudolph U, Fritschy JM, Arand M (2012). Tonic inhibition in principal cells of the amygdala: a central role for a3 subunit-containing GABAA receptors. J Neurosci 32: 8611-8619.
30. Melchior CL, Allen PM (1992). Interaction of pregnanolone and pregnenolone sulfate with ethanol and pentobarbital. Pharmacol Biochem Behav 42: 605-611.
31. Mihalek RM, Banerjee PK, Korpi ER, Quinlan JJ, Firestone LL, Mi ZP et al (1999). Attenuated sensitivity to neuroactive steroids in gamma-aminobutyrate type A receptor d subunit knockout mice. Proc Natl Acad Sci USA 96: 12905-12910.
32. Murphy NP, Maidment NT (1999). Orphanin FQ/nociceptin modulation of mesolimbic dopamine transmission determined by microdialysis. J Neurochem 73: 179-186.
33. Nohria V, Giller E (2007). Ganaxolone. Neurotherapeutics 4: 102-105.
34. Nusser Z, Sieghart W, Somogyi P (1998). Segregation of different GABAA receptors to synaptic and extrasynaptic membranes of cerebellar granule cells. J Neurosci 18: 1693-1703.
35. Nuutinen S, Karlstedt K, Aitta-Aho T, Korpi ER, Panula P (2010). Histamine and H3 receptor-dependent mechanisms regulate ethanol stimulation and conditioned place preference in mice. Psychopharmacology (Berl) 208: 75-86.
36. Peng Z, Hauer B, Mihalek RM, Homanics GE, Sieghart W, Olsen RW et al (2002). GABAA receptor changes in d subunit-deficient mice: altered expression of a4 and g2 subunits in the forebrain. J Comp Neurol 446: 179-197.
37. Ramaker MJ, Strong MN, Ford MM, Finn DA (2012). Effect of ganaxolone and THIP on operant and limited-access ethanol self-administration. Neuropharmacology 63: 555-564.
38. Saal D, Dong Y, Bonci A, Malenka RC (2003). Drugs of abuse and stress trigger a common synaptic adaptation in dopamine neurons. Neuron 37: 577-582.
39. Semyanov A, Walker MC, Kullmann DM (2003). GABA uptake regulates cortical excitability via cell type-specific tonic inhibition. Nat Neurosci 6: 484-490.
40. Sinnott RS, Phillips TJ, Finn DA (2002). Alteration of voluntary ethanol and saccharin consumption by the neurosteroid allopregnanolone in mice. Psychopharmacology (Berl) 162: 438-447.
41. Spigelman I, Li Z, Liang J, Cagetti E, Samzadeh S, Mihalek RM et al (2003). Reduced inhibition and sensitivity to neurosteroids in hippocampus of mice lacking the GABAA receptor d subunit. J Neurophysiol 90: 903-910.
42. Stell BM, Brickley SG, Tang CY, Farrant M, Mody I (2003). Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by d subunit-containing GABAA receptors. Proc Natl Acad Sci USA 100: 14439-14444.
43. Storustovu SI, Ebert B (2006). Pharmacological characterization of agonists at d-containing GABAA receptors: Functional selectivity for extrasynaptic receptors is dependent on the absence of g2. J Pharmacol Exp Ther 316: 1351-1359.
44. Tamamaki N, Yanagawa Y, Tomioka R, Miyazaki J, Obata K, Kaneko T (2003). Green fluorescent protein expression and colocalization with calretinin, parvalbumin, and somatostatin in the GAD67-GFP knock-in mouse. J Comp Neurol 467: 60-79.
45. Tzschentke TM (2007). Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict Biol 12: 227-462.
46. Uusi-Oukari M, Korpi ER (2010). Regulation of GABAA receptor subunit expression by pharmacological agents. Pharmacol Rev 62: 97-135.
47. VanDoren MJ, Matthews DB, Janis GC, Grobin AC, Devaud LL, Morrow AL (2000). Neuroactive steroid 3a-hydroxy-5a-pregnan-20-one modulates electrophysiological and behavioral actions of ethanol. J Neurosci 20: 1982-1989.
48. Vashchinkina E, Panhelainen A, Vekovischeva OY, Aitta-aho T, Ebert B, Ator NA et al (2012). GABA site agonist gaboxadol induces addiction-predicting persistent changes in ventral tegmental area dopamine neurons but is not rewarding in mice or baboons. J Neurosci 32: 5310-5320.
49. Wiltgen BJ, Sanders MJ, Ferguson C, Homanics GE, Fanselow MS (2005). Trace fear conditioning is enhanced in mice lacking the d subunit of the GABAA receptor. Learn Mem 12: 327-333.
50. Zorumski CF, Paul SM, Izumi Y, Covey DF, Mennerick S (2013). Neurosteroids, stress and depression: potential therapeutic opportunities. Neurosci Biobehav Rev 37: 109-122.